Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir Monotherapy in HCV Genotypes 2-6
NCT00812331Phase 2Completed
- Sponsor
- Tibotec
- Start
- Mar 2009
- Primary completion
- Nov 2009
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 2 trial of simeprevir in hepatitis C (HCV), sponsored by Tibotec. Started Mar 2009; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00812331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00812331.